You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. The Alleged CELLECTRA Device Manufacturing Deficiencies The biotechnology sector relies heavily on medical ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Inovio's handheld Cellectra device is essential to ...

What are the allegations? Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device According to the complaint, ...

SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc.

PLYMOUTH MEETING, Pa., June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U.S. Department of Defense (DoD) to support the large-scale ...

Last week the United States Food and Drug Administration (FDA) authorized the biotechnology company Inovio to move forward with clinical trials in the United States to test their DNA-based plasmid ...

Inovio Pharmaceuticals, Inc. INO announced today the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX^®-B preventive HIV DNA vaccine delivered with a ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) that a class action lawsuit has been filed on behalf of shareholders ...